Global trials can unlock real advantages for sponsors, including access to diverse patients, faster enrollment, and more representative data across geographies. However, global expansion isn’t always the right move. For every sponsor that benefits, there’s one that overspends, underdelivers, or enters markets they were never built to support. In a high-risk industry that punishes missteps and rewards efficiency, the question any sponsor should ask isn’t how to go global. It’s whether they should at all.
